Latest News

July 15, 2014

Monoclonal Antibody-based Filovirus Therapeutic Licensed to Leaf Biopharmaceutical

July 29, 2013

International Joint Venture to Drive Commercialization of Filovirus Therapeutic via Monoclonal Antibodies

June 12, 2013

Defence R&D Canada contracts Defyrus Inc. for $4.1M Encephalitis Vaccine Development

Defyrus is active in the dissemination of its technical results at technical, regulatory and government meetings.



Welcome to Defyrus

Vials of vaccineDefyrus is developing drugs to fight infectious viral diseases worldwide for public health and biodefence missions. All of Defyrus’ products have dual use of biodefence and public health, and as such Defyrus collaborates with government agencies and pharmaceutical companies alike in a wide range of infectious disease indications.

In developing our product portfolio, Defyrus strives to discern the most efficient, robust and simple solutions. We are developing products which naturally stimulate the human immune response and which are quick, easy – no needles - and efficient to deliver. An alert and prepared immune system is better prepared to suppress invading pathogenic viruses.

Evolution produced the effective immune-stimulator, Interferon, as an early warning system within our bodies. Viruses have co-evolved complex systems to evade and suppress natural interferon in order to cause sickness. Defyrus’ products re-establish the dominance of the interferon system thereby alerting the immune system of the presence of a virus and wiping out the infection.